EHA 2018 Annual Congress Highlights in Multiple Myeloma

Please Log In or Register to continue.

Release Date: August 22, 2018
Expiration Date: August 22, 2019

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 European Hematology Association (EHA) Annual Meeting. You can view videos from the meeting and listen as they share insights on a variety of abstracts covering topics including, but not limited to: three- versus two-drug regimens; optimizing carfilzomib-based chemotherapy regimens; new anti-CD38 monoclonal antibodies; a new wave of oral therapies for MM; and the importance of minimal residual disease testing among patients with newly diagnosed and relapsed/refractory MM.

This activity provides notable highlights from several important clinical trials including OPTIMISMM, A.R.R.O.W., and INSIGHT MM, among others, as well as data on venetoclax, a BCL-2 inhibitor, as treatment for relapsed/refractory disease. Take advantage of this excellent opportunity to see how the future of treatment in myeloma is continuing to evolve and how these changes may improve outcomes for your patients.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with multiple myeloma
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in multiple myeloma
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in multiple myeloma


EHA Overview from Joshua Richter, MD

  • Dr. Richter reviews key findings from EHA and trials to watch
  • Venetoclax Monotherapy and Combined with Dexamethasone as Targeted Therapy for Relapsed/Refractory t(11;14) Multiple Myeloma (PS1317)

EHA Highlights from Paul G. Richardson, MD

  • Elotuzumab Plus Pomalidomide/Dexamethasone (EPd) vs Pd for Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2, Randomized Open-Label ELOQUENT-3 Study (LB2606)
  • OPTIMISMM: Phase 3 Trial of Pomalidomide, Bortezomib, and Low‐Dose Dexamethasone vs Bortezomib and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with Relapsed/Refractory Multiple Myeloma (S847)
  • Final Results of a Phase IB Study of Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (S850)

EHA Highlights from Saad Z. Usmani, MD, FACP

  • A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care Over 15 Years: First Results from INSIGHT MM, The Largest Global Prospective, Observational MM Study (PS1300)

EHA Highlights from María-Victoria Mateos, MD, PhD

  • Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing Plus Dexamethasone (d) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W. (S849)
  • Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomide (Len)-Refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 (PF579)

Instructions for Participation and Credit

This activity is eligible for credit through August 22, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

María-Victoria Mateos, MD, PhD
Associate Professor of Medicine
University of Salamanca
Salamanca, Spain

Dr. María-Victoria Mateos received her medical degree from the University of Valladolid in Spain and completed her residency in hematology at the University Hospital of
Salamanca, where she also completed a doctoral degree. She is a consultant physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. In addition, she is the Director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Hematology Department.

Dr. Mateos is a member of the International Myeloma Working Group (IMWG), International Myeloma Society (IMS), and has served on the European Hematology Association (EHA) Scientific Program Committee and Advisory Board, and the American Society of Hematology (ASH) Scientific Committee on plasma cell diseases. She is a Councilor on the EHA Board, a member of the Steering Committee for the Society of Hematologic Oncology (SOHO), the International Myeloma Society(IMS) board, and the European School of Haematology (ESH) Scientific Committee. In addition, Dr. Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smoldering multiple myeloma patients that have profoundly influenced current options for treating these patient populations.

Dr. Mateos has published more than 200 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field.  She is associate editor of myeloma in Annals of Haematology, and is a reviewer for journals such as The New England Journal of Medicine, Lancet, and Lancet Oncology.

Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Paul Richardson received his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, and was chief resident at the Royal Marsden Hospital, London. After a clinical fellowship at Baystate Medical Center of Tufts University School of Medicine, he joined Dana-Farber Cancer Institute where he is a Professor of Medicine at the Harvard Medical School. In addition, Dr. Richardson serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma.

Dr. Richardson is board certified in hematology, internal medicine, and medical oncology. He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Lancet Haematology, Clinical Cancer Research, Blood and Bone Marrow Transplantation, JAMA Oncology, and the British Journal of Haematology. Dr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.

Joshua Richter, MD
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Joshua Richter received his undergraduate degree from Johns Hopkins University and his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. Dr. Richter is currently Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He works in the Myeloma Division of the Tisch Cancer Institute at Mount Sinai.

Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s Macroglobulinemia.

Saad Z. Usmani, MD, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina
Clinical Professor of Medicine, UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina

Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani is a Clinical Professor of Medicine at the UNC School of Medicine, Chief of the Plasma Cell Disorder Program, and Director of Clinical Research in Hematologic Malignancies at the Levine Cancer Institute/Atrium Health.

Dr. Usmani is a member of the International Myeloma Working Group, SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. He has served on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, the ASH Committee on Plasma Cell Neoplasia, and the NCI Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 80 peer-reviewed research manuscripts and 100 abstracts at national and international meetings. A specialist in hematology, medical oncology and bone marrow transplantation, Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-027-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-027-081


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. María-Victoria Mateos has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., and Takeda Oncology.

Dr. Paul Richardson has received honoraria related to formal advisory activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, Oncopeptides, AB, and Takeda Oncology. He has received grant support related to research activities from Bristol-Myers Squibb Company, Celgene, and Takeda Oncology.

Dr. Joshua Richter has received honoraria related to formal advisory activities from Celgene Corporation, Janssen Pharmaceuticals, Inc., Karyopharm Therapeutics, and Takeda Oncology, as well as speakers’ bureau activities from Celgene and Janssen.

Dr. Saad Usmani has received honoraria related to formal advisory activities from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Merck & Co., Inc., Seattle Genetics, Inc., Takeda Oncology, and TeneoBio, as well as speakers’ bureau activities from Amgen, Celgene, Janssen, and Takeda Oncology. He has received grant support related to research activities from AbbVie Inc., Amgen, Bristol-Myers Squibb Company, Celgene, Janssen, Pharmacyclics, Inc., Sanofi. Seattle Genetics, Inc., and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.